Prednisone


Description

A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Read more

Pharmacology

Indication

For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum... Read more

Pharmacodynamic

Prednisone, the most commonly-prescribed corticosteroid, is used to treat allograft rejection, asthm... Read more

Mechanism of action

Prednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active... Read more

Absorption

Readily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-ho... Read more

Protein binding

Extensively bound to plasma proteins.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.

Route of elimination

Excreted in the urine as sulfate and glucuronide conjugates.

Toxicity

Information currently not available.


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type
Increased intraocular pressure US
Clinical Trial
Glaucoma US
Clinical Trial
Exophthalmous US
Clinical Trial
Urticaria US
Clinical Trial
Secondary adrenocortical and pituitary unresponsiveness US
Clinical Trial
Decreased carbohydrate tolerance US
Clinical Trial
Manifestations of latent diabetes mellitus US
Clinical Trial
Posterior subcapsular cataracts US
Clinical Trial
Vertigo US
Clinical Trial
Headache US
Clinical Trial
Menstrual Irregularities US
Clinical Trial
Development of Cushingoid state US
Clinical Trial
Suppressed reactions to skin tests US
Clinical Trial
Negative nitrogen balance due to protein catabolism US
Clinical Trial
Increased intracranial pressure with papilledema US
Clinical Trial
Convulsion US
Clinical Trial
Increased requirements for insulin US
Clinical Trial
Increased requirements for oral hypoglycemic agents US
Clinical Trial
Anaphylactic Reaction US
Clinical Trial
Allergic Reaction US
Clinical Trial
Suppression of growth US
  • pediatric
Clinical Trial
Hypersensitivity Reaction US
Clinical Trial
Hypertension US
Clinical Trial
Muscle Weakness US
Clinical Trial
Potassium loss US
Clinical Trial
Hypokalemic alkalosis US
Clinical Trial
Osteoporosis US
Clinical Trial
Tendon Rupture US
Clinical Trial
Steroid myopathy US
Clinical Trial
Loss of muscle mass US
Clinical Trial
Fluid retention US
Clinical Trial
Congestive Heart Failure US
Clinical Trial
Sodium retention US
Clinical Trial
Thin fragile skin US
Clinical Trial
Impaired Wound Healing US
Clinical Trial
Increase in alkaline phosphatase US
Clinical Trial
Increase in aspartate transaminase US
Clinical Trial
Increased sweating US
Clinical Trial
Facial erythema US
Clinical Trial
Ecchymosis US
Clinical Trial
Petechiae US
Clinical Trial
Peptic Ulcer US
Clinical Trial
Pathologic fracture of long bones US
Clinical Trial
Aspetic necrosis of femoral and humeral heads US
Clinical Trial
Vertebral Compression Fractures US
Clinical Trial
Increase in alanine transaminase US
Clinical Trial
Ulcerative esophagitis US
Clinical Trial
Abdominal distension US
Clinical Trial
Pancreatitis US
Clinical Trial

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Systemic fungal infection
      • Drugbank Id: DBCOND0100019

Food Interactions

  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.
  • When Rayos, the delayed-release tablet, is taken without food, Cmax and bioavailability were lower compared to the fed state.

Interactions

Type in a drug name to check for interaction with Prednisone

The metabolism of (R)-warfarin can be increased when combined with Prednisone.
The metabolism of (S)-Warfarin can be increased when combined with Prednisone.
The risk or severity of edema formation can be increased when 1-Testosterone is combined with Prednisone.
The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Prednisone.
The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Prednisone.
The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisone.
The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Prednisone.
The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Prednisone.
The risk or severity of adverse effects can be increased when Prednisone is combined with 2-Methoxyethanol.
The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Prednisone.
The metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Prednisone.
Prednisone may increase the anticoagulant activities of 4-hydroxycoumarin.
The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisone.
The risk or severity of edema formation can be increased when 5-androstenedione is combined with Prednisone.
The metabolism of Prednisone can be decreased when combined with 6-Deoxyerythronolide B.
The metabolism of 6-O-benzylguanine can be increased when combined with Prednisone.
The metabolism of 7-ethyl-10-hydroxycamptothecin can be increased when combined with Prednisone.
The risk or severity of adverse effects can be increased when Prednisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
The metabolism of 9-aminocamptothecin can be increased when combined with Prednisone.
Prednisone may decrease the excretion rate of Abacavir which could result in a higher serum level.

References

    Information currently not available.

Recent Questions